Press release
What's driving the Biosimilars Market Revenue? Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences
According to Market Study Report, Biosimilars Market provides a comprehensive analysis of the Biosimilars market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities of global industry. This report also provides market landscape and market share information in the Biosimilars market.In-house manufacturing of biosimilars held around 75% market share in the year 2018 and is forecasted to grow at around 26.5% over the projection period. Several benefits offered by in-house manufacturing facilities has helped the companies to monitor and assess the production and reduce other costs of delivery and shipping. Also, several other advantages of in-house manufacturing such as flexibility and efficiency of the work will increase the operational and financial capabilities of the company. Hence, currently in-house manufacturing of biosimilar products will have major market share.
Request a sample of this premium report: https://www.marketstudyreport.com/request-a-sample/2057053?utm_source=openpr&utm_medium=RV
Biosimilars Market will exceed USD 69 billion by 2025; as per a new research report.
Biosimilars market is estimate to growth at a significant rate over the forecast period. Biosimilars are estimated to play a substantial role in enhancing public health issue by addressing the customer needs. It is estimated that biosimilars would result in total potential savings of around over USD 100 billion by the year 2020. Increase in demand for biosimilar drugs in order to reduce the healthcare cost will be one of the major market boosting factors.
Growing prevalence of chronic disorders across the globe, especially in developing regions of Asia Pacific and Latin America owing to rise in sedentary lifestyle among the population and growing habit of fast food consumption will result in growing number of people suffering from such diseases. Hence, increased prevalence rate in developed as well as in certain areas in developing nations will augment the demand and adoption rate of biosimilar drugs, fueling the business growth.
However, high biosimilar development cost will be one of the major reasons hampering the adoption rates in under-developed and few developing countries. It takes around 7 to 8 years and costs around USD 100 million to USD 250 million to develop a biosimilar. Hence, high cost related to biosimilar drugs development will continue to hinder market growth over the forecast timeframe.
Request a discount on standard prices of this premium report: https://www.marketstudyreport.com/check-for-discount/2057053?utm_source=openpr&utm_medium=RV
Recombinant non-glycosylated proteins market held the majority market share in the year 2018 and is estimated to grow at around 26.1% over the estimation period. Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor (Filgrastim), insulin and interferon. Recent technological developments in high-throughput analytical techniques and cell technology will help in effective production of products resulting in enhanced sales. Also, recent launch of insulin glargine in major countries and growing demand of filgrastim will further augment the biosimilars market growth.
Application of biosimilars is highest in hematology segment resulting in major market share. The hematology segment accounted for around USD 4,552.1 million revenue in the year 2018. As per the American Society of Hematology, around 3 million American suffer from anemia. Increase in number of people suffering from blood disorders such as neutropenia, anemia etc. will boost the sales of biosimilars.
Development of biosimilars by recombinant DNA technology (rDNA technology) held over 80% market share and was valued at USD 8,123.6 million in the year 2018. Biosimilar products such as human growth hormones, insulin, erythropoietin etc. are manufactured using recombinant DNA technology. The use of rDNA technology improves the capability of the biosimilars to treat ailment immediately and efficiently. Hence, manufacturers use the recombinant DNA technology in order to manufacture biosimilar products.
U.S. dominated the North America biosimilars market and is estimated to witness significant growth at 38.1% over the forecast period. Presence of new technology, state-of-art facilities for biosimilar production, established and big pharma players market presence has resulted in the U.S. capturing majority market share of the North America biosimilars market. Also, recent biosimilar approvals by FDA in the year 2015 will result in rapid biosimilar adoption, augmenting the market growth. During the forecast years, it will witness significant growth owing to relatively low addressable needs.
Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences are some of the major industry participants operating in the global biosimilars market. Various firms are entering in less addressed and high potential geographies in order to expand their industry presence. Also, introduction and development of several biosimilar drug in developing countries by major local companies will result in augmenting the market growth.
Table of Contents
Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Biosimilars industry 360degree synopsis, 2014 - 2025 (USD Million)
2.1.1. Business trends
2.1.2. Type trends
2.1.3. Technology trends
2.1.4. Mode of delivery trends
2.1.5. Material trends
2.1.6. End-use trends
2.1.7. Regional trends
Chapter 3. Biosimilars Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 - 2025 (USD Million)
3.3. Industry impact factors
3.3.1. Growth drivers
3.3.1.1. Growing incidence of cardiovascular disorders globally
3.3.1.2. Rising demand for minimally invasive procedures
3.3.1.3. Advancement in healthcare technology in North America and Europe
3.3.1.4. Unhealthy and hectic lifestyle
3.3.1.5. Growing geriatric population base especially in developing countries
3.3.2. Industry pitfalls & challenges
3.3.2.1. Incidence of Biosimilars failure and recall
3.3.2.2. Stringent regulatory approval procedure
3.4. Growth potential analysis
3.4.1. By type
3.4.2. By technology
3.4.3. By mode of delivery
3.4.4. By material
3.4.5. By end-use
3.5. Porter's analysis
3.6. Competitive landscape, 2018
3.6.1. Strategy dashboard
3.7. PESTEL analysis
Chapter 4. Biosimilars Market, By Type
4.1. Key segment trends
4.2. Coronary Biosimilars
4.2.1. Market size, by region, 2014 - 2025 (USD Million and Units)
4.3. Peripheral vascular Biosimilars
4.3.1. Market size, by region, 2014 - 2025 (USD Million and Units)
4.3.2. Iliac
4.3.2.1. Market size, by region, 2014 - 2025 (USD Million and Units)
4.3.3. Femoral-popliteal
4.3.3.1. Market size, by region, 2014 - 2025 (USD Million and Units)
4.3.4. Renal
4.3.4.1. Market size, by region, 2014 - 2025 (USD Million and Units)
4.3.5. Carotid
4.3.5.1. Market size, by region, 2014 - 2025 (USD Million and Units)
Chapter 5. Biosimilars Market, By Technology
5.1. Key segment trends
5.2. Bare metal Biosimilars
5.2.1. Market size, by region, 2014 - 2025 (USD Million and Units)
5.3. Drug eluting Biosimilars
5.3.1. Market size, by region, 2014 - 2025 (USD Million and Units)
5.4. Bioresorbable Biosimilars
5.4.1. Market size, by region, 2014 - 2025 (USD Million and Units)
Chapter 6. Biosimilars Market, By Mode of Delivery
6.1. Key segment trends
6.2. Self-expandable Biosimilars
6.2.1. Market size, by region, 2014 - 2025 (USD Million and Units)
6.3. Balloon expandable Biosimilars
6.3.1. Market size, by region, 2014 - 2025 (USD Million and Units)
Chapter 7. Biosimilars Market, By Material
7.1. Key segment trends
7.2. Metal
Contact Us:
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release What's driving the Biosimilars Market Revenue? Amgen, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Coherus BioSciences here
News-ID: 2026490 • Views: …
More Releases from Market Study Report LLC
COVID-19 Detection Kits Market Size o witness substantial growth during 2020-202 …
The research report on ‘COVID-19 Detection Kits market’ scrutinizes the current industry scenario to predict market size, market share, and projects valuation for different segmentations of the industry over 2020-2026. It provides business intelligence regarding various factors driving the industry growth in consort with discussing the challenges faced by the industry, and the approaches followed by market players to counter their impact. COVID-19 Detection Kits Market size to grow with…

What's driving the Small Satellite Market trends? Raytheon, Lockheed Martin, Nor …
Market Study Report LLC adds new research on Small Satellite market, which is a detailed analysis of this business space inclusive of the trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, Small Satellite market also includes an in-depth study of the industry competitive scenario.
The global Small Satellite market is valued at 1340 million US$ in 2018…

What's driving the Antibiotics Market trends? Sanofi, Novartis AG, Pfizer Inc., …
Market Study Report LLC has added a new report on Antibiotics market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Antibiotics market in tandem with its competitive terrain.
The antibiotics was valued at US$ 43,348.38 million in 2019 and is…

What's driving the Electrical House (E-House) Market trends? Schneider Electric, …
Market Study Report LLC has added a new report on Electrical House (E-House) market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Electrical House (E-House) market in tandem with its competitive terrain.
Electrical House (E-House), also called Power House, is…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…